Physician Assistant Program year 2024 Reported 2021–2024 Source: CMS Open Payments, 2026 publication

Meredith Arends

Physician Assistant Prairie Village, KS Physician Assistant

NPI 1699294959 CMS profile 10987066

2904 W 73Rd Street, Prairie Village, KS 66208

Open in the dashboard

General payments

$1,870

126 records reported · program years 2021–2024

Research payments

$0

Paid to them · None reported · program years 2021–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Meredith Arends of Prairie Village, KS is reported in the CMS Open Payments database as having received $1,870 across 126 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $39 2
2023 General $291 18
2022 General $754 52
2021 General $787 54

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Meredith Arends
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Meredith Arends were reported at $0. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Meredith Arends Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $787 $132 $37–$438 $132
2022 $754 $155 $48–$522 $149
2023 $291 $167 $52–$557 $160
2024 $39 $178 $55–$600 $164
2025 $0 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. AbbVie, Inc. $864 60 payments
  2. Lilly USA, LLC $224 13 payments
  3. Novo Nordisk Inc $211 12 payments
  4. Janssen Pharmaceuticals, Inc $67 5 payments
  5. Amgen Inc. $63 5 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $61 4 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $61 4 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $44 3 payments
  9. Amarin Pharma Inc. $34 2 payments
  10. Organogenesis Inc. $33 2 payments
  11. Other $208 16 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Food and Beverage $1,870 126 payments
Products named General payments · program years 2021–2024
  1. UBRELVY $476 36 payments
  2. VRAYLAR $225 12 payments
  3. Ozempic $178 10 payments
  4. TRULICITY $171 10 payments
  5. RYBELSUS $161 9 payments
  6. JARDIANCE Diabetes $152 9 payments
  7. QULIPTA $73 5 payments
  8. XARELTO $67 5 payments
  9. JARDIANCE Diabetes $61 4 payments
  10. Kerendia $61 4 payments
  11. Other $794 55 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

126 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record